Japan's regulatory body has given final go-ahead for the first-ever clinical trial testing patient-derived stem cells to treat age-related macular degeneration (AMD), a common form of...
Induced pluripotent stem (iPS) cells are slated to enter a clinical study in Japan for the treatment of age-related macular degeneration. Massayo Takahashi, an opthamologist at...
Approximately 20% of patients diagnosed with dry age-related macular degeneration develop the wet form, which leads to irreversible eye damage and eventual blindness. While the dry...
David Gamm, MD, PhD, and University of Wisconsin colleagues report the first induced pluripotent stem (iPS) cell model of Best disease, a rare, genetic disorder that...
Dieter Egli, a NYSCF Senior Research Fellow, contributed to a study published in Molecular Medicine that provides direct evidence of sight-loss recovery using induced pluripotent stem...
Dieter Egli, a NYSCF Senior Research Fellow, contributed to a study published in Molecular Medicine that provides direct evidence of sight-loss recovery using induced pluripotent stem...
The New York Stem Cell Foundation (NYSCF) announced today that Dr. Peter J. Coffey, a British stem cell scientist working to cure blindness, will be the...
Advanced Cell Technology (ACT) has developed a therapy for Stargardt’s Macular Degeneration using human embryonic stem cells. This is the second clinical trial using embryonic stem cells...
